<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> reduce <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> and increase <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="1" pm="."><plain>In mice with human-like <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> metabolism (APOE*3-Leiden.CETP transgenic mice), a decrease in hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content is associated with a decrease in plasma cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> transfer protein (CETP) mass and an increase in <z:chebi fb="17" ids="39025">HDL</z:chebi> levels </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, the aim of the present study was to assess the effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on CETP mass in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We included 78 men with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (aged 56.5 +/- 0.6 years; HbA1c 7.1 +/- 0.1%) who were randomly assigned to treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> (30 mg/day) or <z:chebi fb="0" ids="6801">metformin</z:chebi> (2000 mg/day) and matching placebo, in addition to <z:chebi fb="0" ids="5383">glimepiride</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>At baseline and after 24 weeks of treatment plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels and CETP mass were measured, and hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content was assessed by proton magnetic resonance spectroscopy </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS <z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> decreased hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content (5.9 [interquartile range 2.6-17.4] versus 4.1 [1.9-12.3]%, P &lt; 0.05), decreased plasma CETP mass (2.33 +/- 0.10 vs. 2.06 +/- 0.10 microg/ml, P &lt; 0.05), and increased plasma <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> level (1.22 +/- 0.05 vs. 1.34 +/- 0.05 mmol/l, P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> did not significantly change any of these parameters </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: A decrease in hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content by <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> is accompanied by a decrease in plasma CETP mass and associated with an increase in <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> levels </plain></SENT>
<SENT sid="8" pm="."><plain>These results in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> fully confirm recent findings in mice </plain></SENT>
</text></document>